Financial review U NOVARTIS | Reimagining Medicine Share buybacks >USD 32bn 2018-2023 New USD 15bn SBB commenced in Jul 2023 Novartis Q4 Results | January 31, 2024 29 Content Click below to navigate through the document • Completed the separation of Sandoz to create an independent company by way of 100% spin-off (Oct 4, 2023) U NOVARTIS | Reimagining Medicine Novartis Sandoz Content Click below to navigate through the document Conclusions 1. Proposal to shareholders at the 2024 Annual General Meeting, takin ...

Novartis in Society Integrated Report 2023 2 Novartis in Society Integrated Report 2023 Contents Who we are | Our approach to reporting | 3 | | --- | --- | | 2023 at a glance | 4 | | Chair's letter | 5 | | CEO's letter | 6 | | We are Novartis | 7 | | Our transformation | 8 | | Our medicines | 9 | | Our global operations | 10 | | Our people, culture and values | 11 | Our operating environment and strategy | Our operating environment | 13 | | --- | --- | | Our strategy | 15 | | Our material issues | 16 | | Ou ...

US Securities & Exchange Commission Form 20-F 2023 U NOVARTIS As filed with the Securities and Exchange Commission on January 31, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE S ...

Analysts on Wall Street project that Novartis (NVS) will announce quarterly earnings of $1.67 per share in its forthcoming report, representing an increase of 10.6% year over year. Revenues are projected to reach $11.69 billion, declining 7.9% from the same quarter last year.Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted upward by 0.3% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Be ...

Swiss pharma giant Novartis AG (NVS) is scheduled to post fourth-quarter 2023 results on Jan 31.The company has an impressive track record, beating the earnings expectations in each of the trailing four quarters. It delivered a four-quarter average earnings surprise of 6.99%. In the last reported quarter, it beat earnings estimates by 2.35%.Let's see how things are shaping up for this announcement.Factors Driving GrowthWith the successful spin-off of the Sandoz business in October 2023, Novartis operates as ...

Novartis AG (NYSE:NVS) 2024 J.P. Morgan 42nd Annual Healthcare Conference Call January 8, 2024 9:00 AM ET Company Participants Vas Narasimhan - Chief Executive Officer Conference Call Participants Richard Vosser - J.P. Morgan Richard Vosser Welcome to the Novartis presentation at the 42nd J.P. Morgan Healthcare Conference. I'm Richard Vosser, European Pharma Analyst with J.P. Morgan. It's my great pleasure to welcome Vas Narasimhan, the CEO of Novartis today. Before I hand over to Vas, I'll just everyone; w ...

Novartis AG (NYSE:NVS) 10th Annual ESG Investor Event Conference November 13, 2023 10:30 AM ET Company Participants Maria Victoria Cuevas - IR Vas Narasimhan - CEO Lutz Hegemann - President, Global Health & Sustainability Thierry Diagana - Head, Global Health Research Sujata Vaidyanathan - Global Development Head Paul Penepent - Head Finance Reporting & Accounting Dr. Klaus Moosmayer - Chief Ethics, Risk & Compliance Officer Maria Victoria Cuevas Good morning and good afternoon. Thank you so much for joinin ...

Operator Thank you. Your next question comes from the line of Florent Cespedes from Societe Generale. Please go ahead. Florent Cespedes Good afternoon. Thank you very much for taking my question. On emerging market, you delivered pretty consistent growth quarter-over-quarter. I was just wondering, how confident are you to continue to deliver such growth? Or is there any loss of exclusivity to come in certain countries, notably in China that could impact this growth trajectory? Thank you. Yeah. Thanks, Flore ...

Insights PSMAfore trial design BPI-SF pain intensity scale2 HR: 0.69 (95% CI: 0.56, 0.85) Novartis Investor Relations Investor Presentation October 24, 2023 This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, that can generally be identified by words such as "potential," "will," "planned," "pipeline," "outlook," or similar expressions, or by express or implied discussions regarding potential marketing approvals, new ...

ianalumab - BAFF-R inhibitor Primary Outcome Measures | --- | --- | --- | --- | --- | --- | |---------------------------------------------------------------|---------------------------------------------|---------------------------|-----------------------------------------------------------|-----------------------------|-------| | Company overview Company overview | Financial review Financial review | Conclusions Conclusions | Appendix Appendix | References References | | | Innovation: Pipeline overview Inno ...